# DEC 16 2005

# Dri-STAT $\circled{8}$ Enzymatic Bilirubin Reagent and Calibrator Section 510(k) Supplemental Information, K053090

510(k) Summary Dri-STAT $\textsuperscript { \textregistered }$ Enzymatic Bilirubin Reagent

# 1.0 Submitted By:

Eri Hirumi Staff Regulatory Affairs Specialist Beckman Coulter, Inc. 200 S. Kraemer Blvd., W-110 Brea, California 92822-8000 Telephone: (714) 961-4389 FAX: (714) 961-4234

# 2.0 Date Submitted:

November 1, 2005

# 3.0 Device Name(s):

3.1 Proprietary Names Dri-STAT $\textsuperscript { \textregistered }$ Enzymatic Bilirubin Reagent SYNCHRON $\textcircled{8}$ Systems Bilirubin Calibrator

3.2 Classification Name Bilirubin (total or direct) test system (21 CFR $\ S$ 862.1110) Calibrator (21 CFR $\ S 8 6 2 . 1 1 5 0 \rangle$ EY

# 4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Candidate(s)</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>DocketNumber</td></tr><tr><td rowspan=1 colspan=1>Dri-STAT®Enzymatic BilirubinReagent</td><td rowspan=1 colspan=1>Dri-STAT®Enzymatic BilirubinReagent</td><td rowspan=1 colspan=1>BeckmanCoulter, Inc.*</td><td rowspan=1 colspan=1>K843174</td></tr><tr><td rowspan=1 colspan=1>SYNCHRON®Systems BilirubinCalibrator</td><td rowspan=1 colspan=1>SYNCHRON®Systems BilirubinCalibrator</td><td rowspan=1 colspan=1>BeckmanCoulter, Inc.*</td><td rowspan=1 colspan=1>K791141</td></tr></table>

\*Beckman Coulter, Inc., Brea, CA

Dri-STAT® Enzymatic Bilirubin Reagent and Calibrator Section 510(k) Supplemental Information, K053090

# 5.0 Description:

The Dri-STAT® Enzymatic Bilirubin Reagent Enzymatic Bilirubin may be used on the family of Synchron Systems in conjunction with the SYNCHRON® Systems Bilirubin Calibrator. The reagent kit contains two reagent bottles that needs to be manually transferred into a Beckman Coulter User-Define Cartridge

# 6.0 Intended Use:

Dri-STAT® Enzymatic Bilirubin Reagent, in conjunction with the SYNCHRON® Systems Bilirubin Calibrator, is intended for use in the in vitro diagnostic determination of total bilirubin in human serum and plasma as a User Defined Reagent (UDR) application on SYNCHRON® Systems.

# 7.0 Comparison to Predicate(s):

The following table shows similarities and differences between the predicates identified in Section 4.0 of this summary.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Similarities</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=7 colspan=1>TBEReagent</td><td rowspan=1 colspan=1>Intended Use</td><td rowspan=7 colspan=1>Same as Beckman CoulterDri-STAT® Enzymatic BilirubinReagent,Enzymatic Bilirubin on Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Methodology</td></tr><tr><td rowspan=1 colspan=1>Reactive Ingredients</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td></tr><tr><td rowspan=1 colspan=1>Shelf Life</td></tr><tr><td rowspan=1 colspan=1>Reaction Type</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Differences</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=5 colspan=1>′</td><td rowspan=1 colspan=1>Instrument Platforms</td><td rowspan=1 colspan=1>SYNCHRON® SystemsVsCobas Fara</td></tr><tr><td rowspan=1 colspan=1>Analytical Range</td><td rowspan=1 colspan=1>Up through 35 mg/dL on predicate0.2 - 25 mg/dL on candidate</td></tr><tr><td rowspan=1 colspan=1>Reference Intervals</td><td rowspan=1 colspan=1>0.1-1.0   mg/dL on predicate0.3-1.2  mg/dL per literature</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>465 nm on predicate470 and 520 nm on candidate</td></tr><tr><td rowspan=1 colspan=1>Reaction Volumes</td><td rowspan=1 colspan=1>0.05; 1.00; 0.08 mL on predicate10; 200; 16 μL on candidate</td></tr></table>

# Dri-STAT® Enzymatic Bilirubin Reagent and Calibrator Section 510(k) Supplemental Information, K053090

# 8.0 Summary of Performance Data:

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. Equivalence is demonstrated through method comparison, linearity, and imprecision experiments.

Dri-STAT Enzymatic Bilirubin Method Comparison Study Results   

<table><tr><td rowspan=1 colspan=1>CandidateMethod</td><td rowspan=1 colspan=1>SampleType</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Inter-cept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Predicate Method</td></tr><tr><td rowspan=1 colspan=1>Dri-STATTBE ReagentOn SynchronLX System</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1.031</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>Beckman CoulterDri-STATEnzymatic Bilirubinon Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Dri-STATTBE ReagentOn SynchronCX System</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1.004</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>Beckman CoulterDri-STATEnzymatic Bilirubinon Cobas Fara</td></tr></table>

Dri-STAT Enzymatic Bilirubin Estimated Imprecision   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>S.D. (mg/dL)</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=5>Within-Run Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 2</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 3</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 2</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 3</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>80</td></tr></table>

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

# DEC 16 2005

Ms. Eri Hirumi   
Staff Regulatory Affairs Specialist Beckman Coulter, Inc.   
200 S. Kraemer Blvd.   
Brea, CA 92822

Re: k053090 Trade/Device Name: Dri- STAT® Enzymatic Bilirubin Reagent Regulation Number: 21 CFR 862.1110 Regulation Name: Bilirubin (total or direct) test system Regulatory Class: Class II Product Code: JFM Dated: November 1, 2005 Received: November 2, 2005

Dear Ms. Hirumi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/754bb66be503ab1be581a658e9ca7cb0944e183fc32e065628d65bab64c21113.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Dri-STAT® Enzymatic Bilirubin Reagent and Calibrator Section 510(k) Supplemental Information, K053090

# Indications for Use

510(k) Number (if known): K053090

Device Name: Dri-STAT® Enzymatic Bilirubin Reagent

Indications For Use:

Dri-STAT® Enzymatic Bilirubin Reagent, in conjunction with the SYNCHRON® Systems Bilirubin Calibrator, is intended for use in the in vitro diagnostic determination of total bilirubin in human serum and plasma as a User Defined Reagent (UDR) application on SYNCHRON® Systems.

Measurements of total bilirubin in serum and plasma are used in the diagnosis of hemolytic disorder, biliary obstruction, hepatitis and cirrhosis

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of

patma Office of H Vitro Dgnostic Device Evaluation and Stiety 5053090